Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Topics Community

Article

Real-World Study of Characteristics and Treatment Outcomes Among Patients with KRAS p.G12C-Mutated or Other KRAS Mutated Metastatic Colorectal Cancer.

The oncologist - 5 Aug 2022

Fakih Marwan, Tu Huakang, Hsu Hil, Aggarwal Shivani, Chan Emily, Rehn Marko, Chia Victoria, Kopetz Scott

Abstract excerpt

BACKGROUND: The KRAS p.G12C mutation has recently become an actionable drug target. To further understand KRAS p.G12C disease, we describe clinicopathologic characteristics, treatment patterns, overall survival (OS), and real-world progression-free survival (rwPFS) in patients with metastatic colorectal cancer (mCRC), KRAS p.G12C mutations (KRAS G12C), and other KRAS mutations (KRAS non-G12C) using a...

Topics

Colonic Neoplasms
Colorectal Neoplasms
Humans
Mutation
Prognosis
Proto-Oncogene Proteins p21(ras)
Rectal Neoplasms
Treatment Outcome

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Open in PubMed Open full text

Identifiers

PMID: 35472176
DOI: 10.1093/oncolo/oyac077
PMCID: PMC9355827

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 31 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Real-World Study of Characteristics and Treatment Outcomes Among Patients with KRAS p.G12C-Mutated or Other KRAS Mutated Metastatic Colorectal Cancer.PMID 35472176Read ↗

Real-world treatment patterns and outcomes based on RAS/BRAF status in metastatic colorectal cancer-Analysis of the Prospective Dutch Colorectal Cancer cohort.Semantic proximity Read ↗

Real-world evaluation of treatment patterns and clinical outcomes in patients with BRAF-V600E metastatic colorectal cancer (mCRC) in Canada.Semantic proximity Read ↗

KRAS Mutation Status as a Prognostic Marker and Predictor of Therapy Response in Colorectal Cancer: an NCDB Analysis.Semantic proximity Read ↗

Real-world treatment and outcomes of patients with metastatic BRAF mutant colorectal cancer.Semantic proximity Read ↗

KRAS-G12C Mutation in One Real-Life and Three Population-Based Nordic Cohorts of Metastatic Colorectal CancerSemantic proximity Read ↗

Prognostic significance of KRAS G12C versus non-G12C RAS mutations in metastatic colorectal cancer: a systematic review and meta-analysis.Semantic proximity Read ↗

Metastatic colorectal cancer treatment patterns according to kirsten rat sarcoma viral oncogene homolog genotype in U.S. Community-based oncology practices.Semantic proximity Read ↗

A Systematic Review of the Efficacy of KRAS p.G12C Inhibitors in Metastatic Colorectal Cancer: The Current State of Science.Semantic proximity Read ↗

The Prognostic Impact of KRAS G12C Mutation in Patients with Metastatic Colorectal Cancer: A Multicenter Retrospective Observational Study.Semantic proximity Read ↗

Evaluation of KRAS and NRAS mutations in metastatic colorectal cancer: an 8‐year study of 10 754 patients in TurkeySemantic proximity Read ↗

KRAS G12C Metastatic Colorectal Cancer: Specific Features of a New Emerging Target Population.Semantic proximity Read ↗

Patients with Colorectal Cancer and BRAFV600E-Mutation in Argentina: A Real-World Study: The EMOGI-CRC01 StudySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.